Clearstead Advisors’s AbCellera Biologics ABCL Stock Holding History

Clearstead Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26	Closed	-$91	–	3659
2026 Q1	$91	Hold	26	–	–	﹤0.01%	2201
2025 Q4	$89	Buy	+26	New	+$116	﹤0.01%	2531

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Clearstead Advisors's ABCL Position: Q2 2026 in Review

Clearstead Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 26 shares — an estimated $91 sold.

Clearstead Advisors first reported a position in ABCL in Q4 2025 and held it in 2 quarters. The position peaked at $91 in Q1 2026. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Clearstead Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Clearstead Advisors sold 26 AbCellera Biologics shares in Q2 2026, an estimated $91.
Clearstead Advisors first reported a position in AbCellera Biologics in Q4 2025 and held it in 2 quarters.
Clearstead Advisors's AbCellera Biologics position peaked at $91 in Q1 2026.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.